Sushil Patel Sells 10,000 Shares of Replimune Group (NASDAQ:REPL) Stock

Replimune Group, Inc. (NASDAQ:REPL) CEO Sushil Patel sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $11.13, for a total transaction of $111,300.00. Following the completion of the transaction, the chief executive officer owned 333,576 shares of the company’s stock, valued at $3,712,700.88. This trade represents a 2.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Replimune Group Trading Up 2.0%

REPL traded up $0.21 during mid-day trading on Thursday, reaching $10.53. The stock had a trading volume of 1,282,111 shares, compared to its average volume of 4,279,576. The firm’s fifty day simple moving average is $7.62 and its two-hundred day simple moving average is $7.53. The stock has a market capitalization of $825.97 million, a P/E ratio of -3.04 and a beta of 0.66. Replimune Group, Inc. has a 52 week low of $2.68 and a 52 week high of $14.80. The company has a debt-to-equity ratio of 0.26, a quick ratio of 6.31 and a current ratio of 6.31.

Replimune Group (NASDAQ:REPL) last released its earnings results on Thursday, November 6th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03). On average, equities analysts predict that Replimune Group, Inc. will post -2.97 EPS for the current year.

Analysts Set New Price Targets

REPL has been the topic of several recent research reports. Leerink Partners raised shares of Replimune Group from a “market perform” rating to an “outperform” rating and raised their target price for the company from $3.00 to $13.00 in a research note on Monday, October 20th. HC Wainwright upgraded shares of Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 price objective on the stock in a report on Monday, October 27th. Leerink Partnrs raised shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Wedbush raised shares of Replimune Group from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $4.00 to $18.00 in a report on Monday, October 20th. Finally, JPMorgan Chase & Co. raised Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 price target on the stock in a research note on Monday, October 20th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $9.75.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of REPL. Readystate Asset Management LP boosted its holdings in shares of Replimune Group by 1,296.2% in the third quarter. Readystate Asset Management LP now owns 2,621,012 shares of the company’s stock valued at $10,982,000 after buying an additional 2,433,292 shares during the period. Braidwell LP lifted its position in Replimune Group by 550.3% in the 3rd quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock valued at $11,523,000 after acquiring an additional 2,327,205 shares in the last quarter. Balyasny Asset Management L.P. boosted its stake in Replimune Group by 507.4% in the 3rd quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock worth $11,012,000 after purchasing an additional 2,195,448 shares during the period. Erste Asset Management GmbH raised its stake in shares of Replimune Group by 13,597.5% in the 3rd quarter. Erste Asset Management GmbH now owns 1,630,000 shares of the company’s stock valued at $7,074,000 after purchasing an additional 1,618,100 shares during the period. Finally, Nuveen LLC bought a new stake in shares of Replimune Group in the first quarter valued at about $6,546,000. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.